Specification transfer of (R)-3-amino-1-butanol into pharmaceutical solid oral and injectable formats begins with salt selection and solid-state characterisation rather than direct processing of the neat free base. The molecule has a molecular weight of 89.14 g/mol and contains a primary amine and a terminal hydroxyl group separated by a three-carbon chain. The primary amine can form Schiff-base adducts with reducing sugars, and the primary alcohol contributes to hygroscopicity and hydrogen-bonding in the solid state. A pharmaceutical-grade lot intended for tablet, capsule, granule, or injection manufacture is therefore handled under process-room relative humidity below 40%, and formulation design avoids lactose monohydrate as a filler because the Maillard reaction between the amine and lactose may generate related substances during accelerated storage at 40°C/75% RH. Candidate counterions such as hydrochloride, fumarate, and 1,2-ethanedisulfonate are screened for crystallinity, melting point, intrinsic dissolution rate, and dynamic vapour sorption behaviour before downstream unit operations. Residual solvent controls follow USP 467, elemental impurity controls follow ICH Q3D, and chiral identity is verified by an enantioselective high-performance liquid chromatographic method because the S-enantiomer must be controlled under ICH Q6A. Published data for this specific configuration is limited; process decisions are therefore based on forced-degradation, pH-solubility, and moisture-sorption studies generated during pharmaceutical development.

Direct Compression of Crystalline Salt Forms in Immediate-Release Tablets

A direct-compression grade hydrochloride salt is evaluated when dose loading exceeds 100 mg and the API salt demonstrates acceptable compactability. The milled salt is passed through a conical mill fitted with a 0.457 mm rasp screen; particle-size distribution is controlled at a d90 below 250 µm to reduce segregation in low-dose blends. Excipients replace lactose with mannitol or dibasic calcium phosphate anhydrous to avoid Maillard reactivity. Magnesium stearate at 0.5–1.0% w/w is added by low-shear tumble blending for 2–5 min; extended lubrication is avoided because hydrophobic film formation over the hygroscopic salt particles can reduce tensile strength and slow dissolution. Compression is performed on a rotary tablet press equipped with B-tooling; main compression force is profiled between 6 kN and 18 kN for a 9 mm round biconvex tool, with precompression force set at 2–4 kN to prevent capping. Tablet hardness is measured by USP 1217, friability by USP 1216, disintegration by USP 701, and dissolution by USP 711 Apparatus II at 50 rpm in 0.01 N HCl or phosphate buffer pH 6.8. If the salt shows low compactability, dry granulation is introduced with a roller compactor at roll pressure 20–40 kN and a 0.8 mm milling screen. In production-scale dry granulation, batch-to-batch variance in granule porosity has been observed when feed-screw speed is changed independently of roll speed; therefore both parameters are locked after design of experiments. Finished tablets are packaged in HDPE bottles with desiccant when the closure moisture vapour transmission rate exceeds 0.5 mg/day.

What Limits Hard-Gelatin Capsule Filling Under High-Humidity Conditions?

Capsule filling is constrained by shell brittleness at low relative humidity and softening at high relative humidity; the hygroscopic amine salt requires control of both process and packaging equilibrium moisture. Powder-in-capsule operations on a dosator or tamping-pin machine require a flowable, non-cohesive formulation. If the direct-compression blend is used, colloidal silicon dioxide at 0.25–0.75% w/w is added as a glidant, and sodium stearyl fumarate may replace magnesium stearate to reduce the dissolution-lag risk associated with hydrophobic lubrication. Fill weight is verified gravimetrically at intervals not exceeding 15 min during filling because the material can gain moisture under ambient conditions. Capsule shells containing the amine salt should be stored at 25°C/60% RH or below; elevated humidity softens gelatin and may accelerate oxidation in the presence of trace peroxides from excipients. Dissolution testing uses USP 711 with a sinker to prevent capsule flotation. For delayed-release presentations, the salt is layered onto mannitol starter beads in a fluid-bed coater with a hydroxypropyl methylcellulose subcoat, followed by a methacrylic acid-ethyl acrylate copolymer enteric coating. The coating dispersion is prepared at 15–20% solids and sprayed at a product temperature of 25–30°C to avoid overwetting the hygroscopic core. Stability under 40°C/75% RH is monitored for related substances, water content, and enantiomeric purity.

In paediatric and geriatric granule presentations, the amino alcohol salt is incorporated into a taste-masked, sachet-filled granule rather than a tablet because dose titration and swallowability are primary constraints in these populations. Wet granulation is acceptable only with non-reducing binders such as povidone K30 or hypromellose E5, and the granulating fluid is purified water or ethanol-water; the primary amine does not undergo Maillard chemistry when reducing sugars are absent. High-shear granulation in a 25 L vertical granulator with an impeller tip speed of 5–12 m/s and a chopper speed of 1,500–3,000 rpm is followed by fluid-bed drying at inlet air temperature 50–60°C until residual moisture is below 1.5%. Granules are milled through a 1.0 mm screen and filled into stick packs by volumetric or gravimetric equipment. Bulk density, tapped density, Carr index, and Hausner ratio are recorded under USP 616; a Carr index below 25% is targeted for machine filling. If taste masking is required, citric acid is not used at high ratio because the primary amine forms a soluble citrate salt that can increase hygroscopicity; instead, a waxy melt-coat of stearic acid or cetyl alcohol is applied in a fluid-bed coater at a product temperature approximately 5°C below the lipid melting point. Low-wavelength ultraviolet detection at 210 nm is used for related-substance HPLC because the amino alcohol lacks a strong chromophore; if the pharmacopoeial method is insufficient, charged-aerosol detection or derivatisation is considered. Final granule batches are controlled for microbial limits by USP 61 and USP 62, water content by USP 921, and related substances by a stability-indicating method.

When Terminal Sterilization Remains Feasible for Primary Amine Hydrochlorides in Aqueous Solution

Injectable solution development first establishes the pH of maximum stability and the extent of primary-amine oxidative degradation in aerobic aqueous conditions. A hydrochloride salt dissolved in Water for Injection at 10–50 mg/mL calculated as free base is titrated to pH 4.5–6.0; the solution is buffered with acetate or citrate at 5–50 mM, provided that the selected buffer does not interact with the amine. Terminal sterilisation by moist heat at 121°C for 15 min is evaluated only after spiked degradation studies demonstrate that related substances and enantiomeric purity remain within ICH Q3B thresholds. If autoclaving increases degradation products above the qualification threshold, the process is switched to aseptic filtration through a 0.22 µm polyethersulfone filter with a 0.1 µm prefilter. Nitrogen purging of the bulk solution reduces headspace oxygen to below 2% because primary amines are susceptible to trace-metal-catalysed oxidation; trace-metal controls under ICH Q3D reduce this risk. Filled vials are tested for particulate matter by USP 788, bacterial endotoxins by USP 85, sterility by USP 71, and osmolality by USP 785; tonicity is adjusted with sodium chloride to 290–310 mOsm/kg unless the formulation requires isotonic mannitol. Rubber stoppers are selected from fluoropolymer-coated chlorobutyl formulations because some uncoated elastomers may release aldehydes that form imine adducts with the primary amine. Published data for this specific configuration is limited; cycle development therefore relies on laboratory-scale thermal-stress data and production-scale filter validation rather than literature kinetic constants.

Collapse Temperature and Residual Moisture Control in Lyophilized Injectables

When aqueous stability does not support a ready-to-use solution, a lyophilised cake is developed from a buffered solution of the hydrochloride or fumarate salt. The formulation is filled at 5–10 mL per 10 mL tubing glass vial and lyophilised with a conservative cycle: freezing to −45°C at 0.5–1.0°C/min, primary drying at shelf temperature −20°C to −10°C and chamber pressure 50–150 mTorr, followed by secondary drying at 30–40°C for 6–12 h until the residual moisture content by Karl Fischer titration is below 1.0%. Mannitol or glycine is incorporated as a crystalline bulking agent to produce a mechanically stable cake; sucrose is used as a cryoprotectant only after forced-degradation screening demonstrates no Maillard-type adduct formation under the proposed pH and temperature conditions. Collapse temperature is measured by freeze-drying microscopy before cycle scale-up; if the collapse temperature is below −25°C, primary drying shelf temperature must remain below that threshold to avoid cake shrinkage. The container–closure system is verified by USP 1207 dye ingress and vacuum decay; residual headspace oxygen is controlled below 2% by nitrogen backfill before stopper seating. Reconstituted solution is tested for subvisible particles by USP 788, sterility by USP 71, and bacterial endotoxins by USP 85. The lyophilisation cycle is scaled from laboratory to production freeze dryers by monitoring product temperature with thermocouples and comparing Pirani and capacitance manometer pressure signals for endpoint detection.

Fixed-dose combination processing of the amino alcohol salt with acid-labile co-actives requires segregation of granulation steps when the co-active is moisture-sensitive or contains an aldehyde functionality. The primary amine in (R)-3-amino-1-butanol can react with aliphatic aldehydes released from autoxidised polysorbate or from some coating systems; polysorbate 80 is replaced with poloxamer 188 or an aqueous dispersion of the coating colourant. A bilayer tablet press with independent first-layer tamping and second-layer compression is preferred when the amino alcohol salt and a co-active have different compaction profiles; first-layer tamping pressure is set at 2–5 kN, and main compression is adjusted until the bilayer hardness and friability meet USP 1217 and USP 1216 specifications for a 13 mm oval tool. The bilayer tablet is coated with a non-aldehyde immediate-release film based on polyvinyl alcohol or hypromellose, and the coating pan is operated at a product temperature of 42–46°C for hypromellose-based systems to avoid moisture uptake. Analytical control includes assay by high-performance liquid chromatography for both actives, content uniformity by USP 905, dissolution by USP 711, and degradation products by ICH Q3B thresholds. If the co-active requires gastric protection, a press-fit or capsule-in-capsule approach is preferred over film coating the amine salt with an enteric polymer, because the primary amine can neutralise the acidic methacrylic acid copolymer and compromise enteric film integrity during storage.